Phase II
Shares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance.
CarTher today announces it has secured approval from the French National Agency for Medicines and Health Products Safety (ANSM) to start a Phase I-II clinical trial of its SonoCloud-9 device in the treatment of recurrent glioblastoma.
Developing treatments to help those struggling with depression, a disorder that can lead to suicide, has become a mission for Shawn Singh, CEO of VistaGen, and his colleagues.
Aslan Pharmaceuticals’ first-line therapy for HER1/HER2 co-expressing cancer tumors failed to meet primary endpoints in a mid-stage trial after 12 weeks of treatment, the company announced Sunday.
The Right to Try Act, signed into law by President Donald Trump last spring, may be seeing its first fruits. A California brain cancer patient who did not qualify for participation in a clinical trial will get the chance to see if an experimental glioblastoma treatment will save his life.
Moderna’s clinical and business update at the JP Morgan Healthcare Conference led the newly public company shares to pop 4.2 percent, a welcome change.
As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.
In an interview with CNBC Monday, Novartis Chief Executive Officer Vas Narasimhan noted that the company is looking to become an entity that doesn’t draw its profits from treating disease, but will make money by providing cures.
Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
Karolinska Development’s portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD).
PRESS RELEASES